RA Capital Management L.P. Invests $5.65 Million in Humacyte, Inc. $HUMA

Key Points

• RA Capital Management L.P. has invested approximately $5.65 million in Humacyte, acquiring over 3.3 million shares, which represents 2.14% of the company's stock.
• Several hedge funds, including Columbia Advisory Partners and Hamilton Lane Advisors, have also recently acquired new stakes in Humacyte, contributing to institutional investors owning 44.71% of the company.
• Humacyte reported a loss of ($0.24) earnings per share for the last quarter, missing analysts' consensus estimates, and had revenue of only $0.30 million against expectations of $0.94 million.

RA Capital Management L.P. bought a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,312,356 shares of the company's stock, valued at approximately $5,648,000. RA Capital Management L.P. owned 2.14% of Humacyte as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in HUMA. Columbia Advisory Partners LLC acquired a new stake in shares of Humacyte in the 1st quarter worth $27,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Humacyte in the 1st quarter worth $37,000. Letko Brosseau & Associates Inc. acquired a new stake in shares of Humacyte in the 1st quarter worth $42,000. Ameriprise Financial Inc. acquired a new stake in shares of Humacyte in the 4th quarter worth $58,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Humacyte in the 4th quarter worth $62,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Analyst Upgrades and Downgrades

HUMA has been the subject of several recent analyst reports. Benchmark reduced their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. HC Wainwright reduced their price objective on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Monday, August 11th. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research note on Sunday, August 17th. Finally, Barclays started coverage on shares of Humacyte in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $3.50 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $9.75.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 591,685 shares of Humacyte stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 591,685 shares of Humacyte stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,482,090 shares of company stock valued at $7,466,382. Insiders own 5.10% of the company's stock.

Humacyte Stock Performance

Shares of HUMA opened at $1.55 on Tuesday. The company has a current ratio of 2.45, a quick ratio of 1.93 and a debt-to-equity ratio of 2.97. The stock has a market cap of $245.47 million, a P/E ratio of -3.44 and a beta of 1.88. The company has a 50-day moving average of $2.13 and a two-hundred day moving average of $2.23. Humacyte, Inc. has a 12-month low of $1.15 and a 12-month high of $6.77.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.94 million. As a group, research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.